The role of hypomethylating agents in myelodysplastic syndrome: Changing the management paradigm

Drorit G. Merkel, Arnon Nagler

Research output: Contribution to journalReview articlepeer-review

Abstract

Modern treatment of myelodysplastic syndromes (MDS) with hypomethylating agents (HMAs) such as azacitidine (Vidaza) and decitabine (Dacogen) has changed the clinical landscape of these disorders. Novel drug combinations of HMAs with histone deacetylase inhibitor therapy may synergistically target different dysregulated molecular mechanisms within MDS clones. This article reviews current trial data concerning the use of the main HMAs in MDS patients where intensive chemotherapy and allogeneic stem cell transplantation is generally not an option. Collated data are presented of the clinical response outcomes, toxicity profiles and prognostic response criteria. Vidaza use in low-risk MDS cases, the selected place of allogeneic stem cell transplantation in older patients with significant comorbidity and the novel drug combination strategies for the future are discussed.

Original languageEnglish
Pages (from-to)665-676
Number of pages12
JournalExpert Review of Hematology
Volume6
Issue number6
DOIs
StatePublished - 2013

Keywords

  • Decitabine
  • High risk
  • Hypomethylating agents
  • Int2
  • Myelodysplastic syndrome
  • Vidaza

Fingerprint

Dive into the research topics of 'The role of hypomethylating agents in myelodysplastic syndrome: Changing the management paradigm'. Together they form a unique fingerprint.

Cite this